Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A landmark "living" umbrella review of bipolar disorder treatments has been turned into a free, interactive online platform — the EBI-BD — letting clinicians and patients filter evidence by drug, outcome, and age group in real time. The tool covers 116 unique treatments and 133 outcomes, grading evidence certainty and even ranking medications based on individual side-effect preferences. Experts call it a valuable resource for keeping up with fast-moving research.
Keeping up with bipolar disorder (BD) research just got a lot easier. A large international team has published a sweeping umbrella review in The BMJ and turned its findings into a free, continuously updated online platform called the Evidence Based Interventions for Bipolar Disorder (EBI-BD). The tool lets clinicians and patients filter treatment evidence by intervention, mood phase, age group, and outcome — all in one place.
The review synthesized 77 network or pairwise meta-analyses, grading the certainty of evidence across medications, brain stimulation, nutraceuticals, psychosocial therapies, and circadian-rhythm-based treatments. Standout findings include strong support for lurasidone, quetiapine, cariprazine, and lamotrigine for bipolar depression in adults, and lithium plus several antipsychotics for mania and maintenance.
A standout feature is a preference-based ranking tool that lets users assign personal weight to specific side effects, generating individualized drug rankings. The database will be updated at least every two years.
Key Takeaways:
Why it matters: Traditional clinical guidelines are often outdated by the time they're published. The EBI-BD's living, preference-sensitive format gives both HCPs and patients a practical, up-to-date resource to guide shared decision-making in a condition where treatment choices are notoriously complex.
